DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DOCS - US26622P1075 - Common Stock
43.79 USD
+0.05 (+0.11%)
43.79 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to DOCS. DOCS was compared to 35 industry peers in the Health Care Technology industry. DOCS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. DOCS is growing strongly while it is still valued neutral. This is a good combination! With these ratings, DOCS could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
DOCS had positive earnings in the past year.
DOCS had a positive operating cash flow in the past year.
In the past 5 years DOCS has always been profitable.
DOCS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of DOCS (20.13%) is better than 100.00% of its industry peers.
DOCS's Return On Equity of 23.10% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 18.16%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for DOCS is significantly above the industry average of 6.61%.
The last Return On Invested Capital (18.16%) for DOCS is above the 3 year average (14.17%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROIC | 18.16% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
The Profit Margin of DOCS (40.72%) is better than 100.00% of its industry peers.
In the last couple of years the Profit Margin of DOCS has grown nicely.
Looking at the Operating Margin, with a value of 39.72%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
DOCS's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 90.20%, DOCS belongs to the best of the industry, outperforming 97.14% of the companies in the same industry.
DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
DOCS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, DOCS has more shares outstanding
The number of shares outstanding for DOCS has been increased compared to 5 years ago.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
DOCS has an Altman-Z score of 32.84. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
DOCS has a better Altman-Z score (32.84) than 97.14% of its industry peers.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 32.84 |
ROIC/WACC1.88
WACC9.68%
2.3 Liquidity
DOCS has a Current Ratio of 7.79. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 7.79, DOCS belongs to the best of the industry, outperforming 91.43% of the companies in the same industry.
A Quick Ratio of 7.79 indicates that DOCS has no problem at all paying its short term obligations.
DOCS has a better Quick ratio (7.79) than 91.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.43%, which is quite impressive.
The Earnings Per Share has been growing by 79.21% on average over the past years. This is a very strong growth
The Revenue has grown by 20.21% in the past year. This is a very strong growth!
Measured over the past years, DOCS shows a very strong growth in Revenue. The Revenue has been growing by 37.42% on average per year.
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
3.2 Future
DOCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.75% yearly.
Based on estimates for the next years, DOCS will show a quite strong growth in Revenue. The Revenue will grow by 11.49% on average per year.
EPS Next Y14.22%
EPS Next 2Y11.46%
EPS Next 3Y11.79%
EPS Next 5Y14.75%
Revenue Next Year14.06%
Revenue Next 2Y12.55%
Revenue Next 3Y12.02%
Revenue Next 5Y11.49%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
DOCS is valuated quite expensively with a Price/Earnings ratio of 26.70.
Compared to the rest of the industry, the Price/Earnings ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 80.00% of the companies listed in the same industry.
DOCS is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 25.00, which indicates a rather expensive current valuation of DOCS.
Based on the Price/Forward Earnings ratio, DOCS is valued a bit cheaper than the industry average as 68.57% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 23.92. DOCS is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.7 | ||
| Fwd PE | 25 |
4.2 Price Multiples
62.86% of the companies in the same industry are more expensive than DOCS, based on the Enterprise Value to EBITDA ratio.
74.29% of the companies in the same industry are more expensive than DOCS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.42 | ||
| EV/EBITDA | 25.75 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of DOCS may justify a higher PE ratio.
PEG (NY)1.88
PEG (5Y)0.34
EPS Next 2Y11.46%
EPS Next 3Y11.79%
5. Dividend
5.1 Amount
DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
43.79
+0.05 (+0.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners91.38%
Inst Owner Change0%
Ins Owners1.96%
Ins Owner Change0.19%
Market Cap8.24B
Revenue(TTM)621.33M
Net Income(TTM)253.03M
Analysts77.86
Price Target69.67 (59.1%)
Short Float %5.99%
Short Ratio3.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.98%
Min EPS beat(2)16.41%
Max EPS beat(2)17.55%
EPS beat(4)4
Avg EPS beat(4)25.31%
Min EPS beat(4)16.41%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)23.42%
EPS beat(12)12
Avg EPS beat(12)22.47%
EPS beat(16)16
Avg EPS beat(16)28.98%
Revenue beat(2)2
Avg Revenue beat(2)3.67%
Min Revenue beat(2)2.52%
Max Revenue beat(2)4.82%
Revenue beat(4)4
Avg Revenue beat(4)4.22%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)7
Avg Revenue beat(8)3.68%
Revenue beat(12)9
Avg Revenue beat(12)2.53%
Revenue beat(16)12
Avg Revenue beat(16)2.69%
PT rev (1m)-0.18%
PT rev (3m)-1.81%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)0.27%
EPS NY rev (1m)0.18%
EPS NY rev (3m)4.31%
Revenue NQ rev (1m)0.06%
Revenue NQ rev (3m)0.93%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)1.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.7 | ||
| Fwd PE | 25 | ||
| P/S | 13.27 | ||
| P/FCF | 26.42 | ||
| P/OCF | 25.79 | ||
| P/B | 7.53 | ||
| P/tB | 8.49 | ||
| EV/EBITDA | 25.75 |
EPS(TTM)1.64
EY3.75%
EPS(NY)1.75
Fwd EY4%
FCF(TTM)1.66
FCFY3.79%
OCF(TTM)1.7
OCFY3.88%
SpS3.3
BVpS5.82
TBVpS5.16
PEG (NY)1.88
PEG (5Y)0.34
Graham Number14.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROCE | 22.1% | ||
| ROIC | 18.16% | ||
| ROICexc | 85.05% | ||
| ROICexgc | 177.37% | ||
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% | ||
| FCFM | 50.23% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 64.81% | ||
| Cap/Sales | 1.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 123.66% | ||
| Profit Quality | 123.35% | ||
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 | ||
| Altman-Z | 32.84 |
F-Score9
WACC9.68%
ROIC/WACC1.88
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
EPS Next Y14.22%
EPS Next 2Y11.46%
EPS Next 3Y11.79%
EPS Next 5Y14.75%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
Revenue Next Year14.06%
Revenue Next 2Y12.55%
Revenue Next 3Y12.02%
Revenue Next 5Y11.49%
EBIT growth 1Y22.24%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year17.72%
EBIT Next 3Y13.76%
EBIT Next 5Y14.23%
FCF growth 1Y94.7%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y93.3%
OCF growth 3Y29.24%
OCF growth 5Y59.83%
DOXIMITY INC-CLASS A / DOCS FAQ
What is the fundamental rating for DOCS stock?
ChartMill assigns a fundamental rating of 7 / 10 to DOCS.
What is the valuation status for DOCS stock?
ChartMill assigns a valuation rating of 4 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.
How profitable is DOXIMITY INC-CLASS A (DOCS) stock?
DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.
What are the PE and PB ratios of DOXIMITY INC-CLASS A (DOCS) stock?
The Price/Earnings (PE) ratio for DOXIMITY INC-CLASS A (DOCS) is 26.7 and the Price/Book (PB) ratio is 7.53.
What is the earnings growth outlook for DOXIMITY INC-CLASS A?
The Earnings per Share (EPS) of DOXIMITY INC-CLASS A (DOCS) is expected to grow by 14.22% in the next year.